Partner Therapeutics Reports the US FDA sBLA Submission of Bizengri for NRG1 Fusion Positive Cholangiocarcinoma

Why It Matters

An FDA‑approved Bizengri would fill a critical therapeutic gap for NRG1‑fusion cholangiocarcinoma, offering a precision‑medicine option and expanding Partner Therapeutics' oncology portfolio. It also underscores the growing clinical relevance of rare gene fusions as actionable targets across solid tumors.

Key Takeaways

• Bizengri sBLA submitted for NRG1‑fusion cholangiocarcinoma
• eNRGy trial showed 36.8% ORR, 12.9‑month median duration
• NCCN lists Bizengri as Category 2A subsequent, 2B frontline therapy
• Targets rare NRG1 fusion, offering first FDA‑backed option

Pulse Analysis

Cholangiocarcinoma, a cancer of the bile ducts, remains one of the most lethal gastrointestinal malignancies, with limited treatment options once disease becomes unresectable or metastatic. A small subset of these tumors harbors fusions of the neuregulin‑1 (NRG1) gene, creating an oncogenic driver that is not addressed by conventional chemotherapy or immunotherapy. The rarity of NRG1 fusions—estimated in less than 1% of cholangiocarcinoma cases—has historically impeded drug development, leaving patients with few targeted alternatives and poor prognoses.

Bizengri (zenocutuzumab‑zbco) is a bispecific antibody that simultaneously blocks the ligand‑dependent activation of HER3 and the downstream signaling pathways driven by NRG1 fusions. In the pivotal eNRGy trial, patients with NRG1‑fusion positive cholangiocarcinoma achieved a 36.8% overall response rate, and responders enjoyed a median duration of response of 12.9 months, outcomes that surpass historical benchmarks for this disease. The data prompted the NCCN to elevate Bizengri to Category 2A for subsequent therapy and Category 2B as a frontline option, signaling strong clinical endorsement and paving the way for broader adoption once regulatory clearance is granted.

The sBLA filing marks a watershed moment for precision oncology in rare cancers. If approved, Bizengri would become one of the first FDA‑cleared agents specifically targeting NRG1 fusions, potentially catalyzing further investment in biomarker‑driven drug discovery. For Partner Therapeutics, the approval could unlock a niche market with high unmet need, generate meaningful revenue, and strengthen its pipeline credibility. Moreover, the success of Bizengri may encourage regulators and payers to support accelerated pathways for other low‑prevalence genomic alterations, accelerating the shift toward individualized cancer care.